No abstract available.

No abstract available.
Precursor Cell Lymphoblastic Leukemia-Lymphoma*

An immunohistochemistry for S-100 protein by biotin avidin system technique was done to evaluate the existence and distribution pattern of S-100 protein positive cells in various obtained were as follows. 1) Positive immunostaining for S-100 protein was observed in myoepithelial cell, serous acinar cell and nervous bundle in normal salivary gland. 2) Strong immunoreactivity for S-100 protein was shown in plemorphic adenoma, which was localized not only in myoepithelial cord or sheets of epithelial portion but also in chondrocytes, stellate cells of myxoid stroma and in squamous keratin pearl of mesenchymal metaplastic foci. 3) The S-100 protein was demonstrated in the tumor cells of tubular adenoma, acinic cell tumors and in epidermoid area of mucoepidermoid tumors. 4) Immunoreactivity for S-100 protein, however, was not found in the tumor cells of adenoid cystic carcinoma and adenolymphoma except for stroma reticulum cells. 5) Intensity of positive reaction for S-100 protein varied from cell to cell: Some had intense immunoreactivity, whreas others were only weakly positive or completely negative, even in myoepithelial cell nest of the same pleomorphic adenoma.

BACKGROUND: To prevent the platelet refractoriness, repeated plateletpheresis is often required in HLA matched single-donors. Korean Transfusion Standard permits the repeated plateletpheresis of a single donor at 72-hour intervals. To evaluate this standard, hematological responses of donors were assessed after plateletpheresis by Haemonetics V50 (Haemonetics Co., USA). METHODS: The pre- and post-donated hematological indices of 22 healthy donors(17 males and 5 females) were evaluated. Single donated donors were 12 males and 4 females. Multiple donated donors were 5 males and one female. Post-donated platelet counts were measured immediately, 6 hours, 12 hours, 1 day, 3 days, 5 days, 7 days and 9 days after plateletpheresis. Platelet aggregation test, serum protein, PT, and aPTT were also examined before and after platelet collection. RESULTS: Only 9 (56.2%) of 16 single-donated donors and 4 (66.7%) of 6 multiple donated donors showed normal restoration up to 97% of platelet counts of pre-donation levels at the day 3. In 9 (75%) of 12 single donated males restoration of platelet count was observed within 3 days, but 3 (75%) of 4 single donated females showed restoration of platelet count within 5 days. Changes of other indices were not significantly different between the pre- and post-donations of platelet. CONCLUSIONS: Although no clinical complication was noted after plateletpheresis, these data suggested that Korean Transfusion Standard on plateletpheresis should be reconsidered.
Blood Platelets ; Female ; Humans ; Male ; Platelet Aggregation ; Platelet Count ; Plateletpheresis* ; Tissue Donors*

BACKGROUND: The purpose of this study was to investigate genetic polymorphisms of cytochrome P4502E1 (CYP2E1) among healthy control and alcoholic Koreans in order to determine its relation-ship to the development of alcoholism. We also evaluate the diagnostic usefulness of carbohydrate deficient transferrin (CDT) in alcoholism. METHODS: The healthy control group included 72 males and 32 females. Patients with alcoholism included 53 males and 12 females who met DSM-IV diagnostic criteria (American Psychiatric Asso-ciation, 1994) and were admitted to alcoholism treatment units. Rsa I and Pst I restriction fragment length polymorphisms of CYP2E1 gene PCR product determined the genotype of CYP2E1. The serum level of CDT was analyzed by Behring Nephelometer II using %CDT turbidimetric immunoassay kit. RESULTS: The prevalence of CYP2E1 genotypes was 74.0% for type A, 23.1% for type B, and 2.9% for type C in the 104 healthy subjects, and 93.8% for type A and 6.2% for tyupe B in the 65 patients with alcoholism. The allele frequency of c1 and c2 of CYP2E1 was 85.6% and 14.4%, respectively, in the control group and 96.9% and 3.1%, respectively, in the alcoholics. The %CDT range in healthy controls and alcoholics was 0-7.8% and 3.1-21.1%, respectively. The serum CDT level in the patients with alcoholism (14.4 +/-4.5, mean +/-SD) was higher than that of healthy controls (3.2 +/-1.2, ) (P<0.05). The sensitivity, specificity, positive predictive value, negative predictive value, false positive rate, false negative rate, and test efficiency of %CDT were 85.1%, 93.3%, 88.7%, 90.6%, 6.7%, 15.4%, and 89.9%, respectively. CONCLUSIONS: There was a significant difference in frequencies of CYP2E1 genotype (P=0.001) and allele (P=0.003) between patient with alcoholism and control group, and the absence of CYP2E1 c2 allele was associated with alcoholism. Assessment of CDT yielded useful and objective informa-tion in the diagnosis and identification of alcoholism.
Alcoholics ; Alcoholism* ; Alleles ; Cytochrome P-450 CYP2E1 ; Cytochromes* ; Diagnosis ; Diagnostic and Statistical Manual of Mental Disorders ; Female ; Gene Frequency ; Genotype ; Humans ; Immunoassay ; Male ; Polymerase Chain Reaction ; Polymorphism, Genetic* ; Polymorphism, Restriction Fragment Length ; Prevalence ; Sensitivity and Specificity ; Transferrin*

Vibrio vulnificus infection is one of the most fatal diseases in Korea. This study was undertaken to determine the cellular fatty acid (CFA) compositions of ninety-five clinical strains of V. vulnificus isolated from Korea during 1985-1995. We compared these results with the CFA profile of V. vulnificus in the Microbial Identification System (MIS) (CLIN library version 3.9; Microbial ID Inc., Newark, Del.), and also evaluated the MIS ability to identify V. vulnificus. Subgrouping of V. vulnificus by CFA analysis was performed and its results were compared with those of serotyping. Most of the CFAs in V. vulnificus strains were similar to the CFA profile of V. vulnificus in the MIS, but some distinctive differences were observed. First, means of two major CFAs, 16:0 and 16:1w7c, were 22.16% and 18.26% in this study, but 23.52% and 25.44% in the MIS respectively. Second, all isolates had 11:Oiso3OH, which was not present in the MIS. Eighty-five strains (89.5%) disclosed the first choice identification of V. vulnificus by the MIS, but only two strains (2.1%) were identified with SI values of 0.6. Remaining ten strains (10.5%) showed 'NO MATCH' results. Cluster analysis of CFA could separate V. vulnificus into nine subgroups, and predominant subgroups were subgroup VII (45 strains) and V (36 strains). There was heterogeny between subgroups by CFA and serotypes of V. vulnificus. The strains of 04 serotype which accounted for 80% (76/95) of the isolates were distributed into six different subgroups such as VII (40 strains), V (27 strains), III (4 strains), I (2 strains) and VI (1 strain). These showed that V. vulnificus strains isolated from Korea had different characteristics in the CFA composition in comparison with the MIS V. vulnificus library. Subgrouping by the CFA analysis might be a useful tool for the epidemiological study of V. vulnificus infection in Korea.
Korea* ; Serotyping ; Vibrio vulnificus* ; Vibrio*

We report a case of B-cell chronic lymphocytic leukemia (CLL) with trisomy 12 detected by FISH using chromosome 12 alpha-satellite Probe (Oncor , USA) in uncultured interphase cells. Chromosome studies did not produce an analyzable metaphase by standard short term culture and revealed only normal female karyotype by B cell mitogen (phorbol 12-myristate 13-acetate) stimulated 96 hr culture. The patient, a 59-year-old female, did not have hepatomegaly, splenomegaly, lymphadenopathy and any other symptoms. The peripheral blood of the patient showed marked lymphocytosis (WBC : 28,300/microL, Lymphocyte: 80%) and the diagnosis by immunophenotyping was B cell CLL:CD5, CDl9, CD2O, SmIg, HLA-DR positive.
Chromosomes, Human, Pair 12 ; Diagnosis ; Female ; Fluorescence* ; Hepatomegaly ; HLA-DR Antigens ; Humans ; Immunophenotyping ; In Situ Hybridization* ; Interphase ; Karyotype ; Leukemia, Lymphocytic, Chronic, B-Cell* ; Lymphatic Diseases ; Lymphocytes ; Lymphocytosis ; Metaphase ; Middle Aged ; Splenomegaly ; Trisomy*

We report a case of B-cell chronic lymphocytic leukemia (CLL) with trisomy 12 detected by FISH using chromosome 12 alpha-satellite Probe (Oncor , USA) in uncultured interphase cells. Chromosome studies did not produce an analyzable metaphase by standard short term culture and revealed only normal female karyotype by B cell mitogen (phorbol 12-myristate 13-acetate) stimulated 96 hr culture. The patient, a 59-year-old female, did not have hepatomegaly, splenomegaly, lymphadenopathy and any other symptoms. The peripheral blood of the patient showed marked lymphocytosis (WBC : 28,300/microL, Lymphocyte: 80%) and the diagnosis by immunophenotyping was B cell CLL:CD5, CDl9, CD2O, SmIg, HLA-DR positive.
Chromosomes, Human, Pair 12 ; Diagnosis ; Female ; Fluorescence* ; Hepatomegaly ; HLA-DR Antigens ; Humans ; Immunophenotyping ; In Situ Hybridization* ; Interphase ; Karyotype ; Leukemia, Lymphocytic, Chronic, B-Cell* ; Lymphatic Diseases ; Lymphocytes ; Lymphocytosis ; Metaphase ; Middle Aged ; Splenomegaly ; Trisomy*

A 16-year-old boy was diagnosed with acute lymphoblastic leukemia with dic(9;12). Physical examination revealed cervical lymphadenopathy and splenomegaly. Hemoglobin was 5.1 g/dL, WBC was 4,400/microL and the platelet count was 3,000/ L. Immunophenotyping showed positivity of HLA-DR, CD34, CD10, CD19, CD20, and CD22. The chromosome analysis of bone marrow aspirate showed 46,XY,+8,dic(9;12)(p11-13;p11-12). There has been a complete remission by induction chemotherapy as of the 62nd day.
Adolescent ; Bone Marrow ; HLA-DR Antigens ; Humans ; Immunophenotyping ; Induction Chemotherapy ; Lymphatic Diseases ; Male ; Physical Examination ; Platelet Count ; Precursor Cell Lymphoblastic Leukemia-Lymphoma* ; Splenomegaly ; Trisomy*

BACKGROUND: Peripheral blood stem cell transplantation (PBSCT) has been widely used as a substi-tute of bone marrow transplantation for the treatment of various solid tumors or hematologic malig-nancies. The success of PBSCT is correlated with peripheral blood CD34+ cell count per kilogram of the recipient body weight. Standardization of flow cytometric CD34+ cell enumeration was improved by the modified International Society of Hematotherapy and Gene Engineering (ISHAGE) protocol. The purpose of this study was to evaluate the peripheral parameters (WBCs, mononuclear cells, the CD 34+ cells) that may predict the total CD34+ cell count in the harvest product, using the Stem-Kit (Beck-man Coulter Inc., Fullerton, CA, USA). METHODS: The study tested 88 PBSC harvests and peripheral blood (PB) on the day before collection from 26 patients. The CD34+ cells were analyzed using the Stem-Kit. The WBC and MNC count were measured by Coulter STKS (Beckman Coulter Inc.). The correlation and regression analysis between peripheral parameters (WBCs, MNCs, CD34+ cells) and the total CD34+ cell count in the harvest product were performed. RESULTS: The CD34+ cell count per weight (kg) of 88 PBSC harvests was 1.59 +/- 2.61 (0.01 -17.35). The mean number of WBC, MNC, and CD34+ cell in PB prior to harvest were 10.57 +/- 8.36 (1.50 - 32.50) X 10(3)/micro L, 1.85 +/- 1.28 (0.39- 7.43) X 10(3)/micro L, and 17.21 +/- 33.19 (0.12-239.19)/micro L, respectively. With the CD34+ cells numbering under 3/micro L in peripheral blood (PB), we could not harvest more than 0.5 X 10(6) /kg PBSC. With the cells numbering 3-6/micro L (59%) and 10- 20/micro L (89%), however, we could harvest more than 0.5 X 10(6) /kg and 1.0 X 10(6) /kg, respectively. More than 2.0 X 10(6)/kg of PBSC was collected with 10-20/micro L (31%). The peripheral blood CD34+ cell count prior to harvest significantly correlated with the total CD34+ cell count in the harvest product (r=0.97, P<0.05). CONCLUSIONS: Peripheral blood CD34+ cell enumeration using the Stem-Kit was an efficient predictor of when to harvest peripheral blood stem cells after mobilization therapy. We could not collected the CD34+ cell in harvest product of more than 0.5 X 10(6)/kg if the peripheral blood CD34+ cell count was less than 3/micro L.
Body Weight ; Bone Marrow Transplantation ; Cell Count* ; Humans ; Peripheral Blood Stem Cell Transplantation ; Stem Cells*